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Abstract
Background: Typical carcinoid syndrome is characterized by flushing, abdominal pain and diarrhea and occurs in
<10 % of carcinoid tumor patients. Very rarely, initial signs include skin manifestations. Our purpose is to highlight
cutaneous manifestations in the diagnosis and assessment of a patient with atypical manifestation of type I gastric
carcinoid tumor.
Case presentation: A 50-year-old woman presented with anemia, chronic urticaria and angioedema. Urticaria was
triggered principally by seafood and appeared in the first hour after. Urticaria Activity Score 7 was 24, and quality
of life (CU-Q2oL) was 3.61. P. Laboratory findings showed anemia, diminished iron, ferritin, and vitamin B12, with
increased gastrin and anti-parietal cell antibody levels. 15 gastric carcinoids 5 mm in diameter were observed in the
greater curvature of the stomach during gastric endoscopy and confirmed by biopsy, suggesting that this patient
had type I gastric carcinoids. Four additional tumors were found in the small intestine upon examination via video
capsule. Endoscopic argon plasma therapy was performed. The patient experienced definitive improvement in
quality of life and urticaria activity score.
Conclusion: This patient, whose principal symptoms were anemia, urticaria and angioedema, was found to have
atypical carcinoid syndrome, with tumors located in the stomach. Allergists, immunologists, internists and primary
care physicians should consider the possibility of neuroendocrine malignancies, specifically type I carcinoid tumors,
when evaluating patients with urticaria, and consider screening patients with chronic urticaria for elevated anti-parietal
cell antibody levels.
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Background
Carcinoid tumors are rare, slow-growing neuroendocrine
tumors arising from the enterochromaffin cells. They are
most commonly found in the gastrointestinal tract (64 %)
[1], although they can involve any organ. These tumors
can secrete biogenic amines and peptides, such as ACTH,
5-HTP and serotonin [2]. Classical carcinoid syndrome
occurs in <10 % of patients with carcinoid tumors. Its
most typical clinical manifestations include cutaneous
flushing, most often on the face, neck, and upper chest,
diarrhea and abdominal pain [3]. Other manifestations
may occasionally be encountered, including bronchial
asthma, wheezing, or very rarely, skin manifestations [4].
Gastric carcinoid tumors are classified as those associ-
ated with chronic gastritis type A (CAG-A, or type I),
those that concur with the Zollinger-Ellison syndrome
(type II), and sporadic gastric tumors (type III). Type I
gastric carcinoids account for 70 to 80 % of neuroendocrine
gastric malignancies. They are associated with autoimmune
atrophic gastritis, hypergastrinemia, and pernicious anemia
[5]. Type I gastric carcinoids often measure less than 1 cm
in diameter and are typically located in the body or fundus
of the stomach [6, 7]. They are multicentric, polypoid,
small, limited to the mucosa or submucosa, without angio-
invasion, well-differentiated, and tend to display a benign
behavior. They primarily affect women between the ages of
50 and 70 years and have a good prognosis, with a low rate
of metastasis ranging between 2 and 5 % [8].
More than half of patients with CAG-A–associated car-
cinoids also have pernicious anemia. Pernicious anemia is
associated with increased the risk of gastric carcinoid
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tumors, presumably due to prolonged achlorhydria. It re-
sults in parietal cell loss, compensatory hypergastrinemia,
and argyrophilic cell hyperplasia [9].
Persistent achlorhydria produces G cell hyperplasia
and more gastrin secretion, leading to hypergastrinemia
[10]. Gastrin stimulates CCK-B/gastrin receptor (CCK2R)
which further activates genes that encode HDC (histidine
decarboxylase), VMAT2 (vesicular monoamine transporter
molecule 2) and CgA (Chromogranin-A), but the signaling
pathway leading to enterochromaffin cells hyperplasia re-
mains unknown [11]. The widespread use of proton pump
inhibitors can also induce gastric achlorhydria, thus con-
tributing to hypergastrinemia.
Type II carcinoids present with hypergastrinemia and
are associated with Zollinger-Ellison syndrome. In con-
trast to type I gastric carcinoids, the hypergastrinemia
associated with type II gastric carcinoids is secondary to
gastrin secreting G cell neoplasia rather than parietal cell
loss. Type II gastric carcinoids are very uncommon; the
majority have good prognosis. The last type of gastric car-
cinoid, type III, may be associated with atypical carcinoid
syndrome [12, 13]. Atypical carcinoid syndrome is mani-
fested by flushing, and tumors tend to be metastatic at
their presentation, and thus have the worst prognosis [14].
Radical gastrectomy is the most common treatment for
type III gastric carcinoids [15].
Here we report urticaria, angioedema and anemia as
symptoms in an atypical presentation of type I gastric
carcinoid. Our purpose is to highlight the relevance of
cutaneous manifestations in the diagnosis and assessment
of a patient with an underlying neuroendocrine malig-
nancy. We also remark on the effectiveness of endoscopic
ablation. And we encourage all medical practitioners to be
aware that skin changes may provide an early clue for clin-
ical management of gastric carcinoids.
Case presentation
We report a case of a 50-year-old woman with atypical
type I gastric carcinoid tumor. The patient presented with
anemia, chronic urticaria and angioedema. The urticaria
began one year prior to her evaluation by us, and was trig-
gered by seafood. Other triggers included vitamin B12,
desserts, and maize, as well as friction from shoes while
running, and doing handicrafts. Lesions usually began in
the first hour after the stimuli. Three months prior to de-
veloping urticaria, the patient was diagnosed with anemia.
In the year since her urticaria began, the patient had lost
20 pounds without effort. She reported that her symptoms
improved after taking the proton pump inhibitor (PPI)
pantoprazole, but she only used the PPI sporadically. The
reason for this response to PPI is not clear.
Initial symptoms of the urticaria were nausea ac-
companied by erythema, edema, pruritus and wheals.
Wheals were larger than 5 mm, and were accompanied by
erythema. They were associated with pain, burning and
morning-time livedo reticularis. Wheals lasted more than
12 h, and were localized in palm, soles, armpits, feet,
hands, buttocks, shoulders, trunk, legs and back. The pa-
tient also experienced generalized angioedema, which was
triggered by seafood, corn, some desserts and ibuprofen,
as well as blurred vision and sore throat. Urticaria Activity
Score 7 (UAS 7) was 24, and the mean score on the CU-
Q2oL quality of life measure was 3.61. Fecal exam,
immunological tests (complement levels and immuno-
globulins) and skin prick allergy tests for shrimp, crab,
dust mite, and dog hair were all normal. There were no
signs of vasculitis in the skin biopsy.
Laboratory tests showed diminished iron, ferritin, and
vitamin B12 (patient had stopped taking B12, as it trig-
gered the hives). The gastrin level was 286 pg/ml (refer-
ence value <100 pg/ml) and parietal cell antibody was
106.53 U/ml (reference value Negative: < or =20.0 U,
Equivocal: 20.1-24.9 U, Positive: > or =25.0 U) [16]. RDW
(Red Cell Distribution Width) was high, and anisocytosis
was found. Microcytosis was also observed, perhaps due
to iron deficiency, as well as megaloblasts.
Gastric endoscopy was performed and 15 sessile polyps
with diameter of 5 mm were observed in the greater
curvature of the stomach (three in the antrum and 12 in
the body). Three in the antrum were extirpated (biopsy)
and sent to pathology; the rest were subjected to plasma
argon ablation (Fig. 1a-b). Also, biopsy of hyperplasia of
mucosae located in the antrum of the greater curvature of
the stomach was taken. No H. pylori bacilli were present,
as determined by toluidine blue, but mild chronic gastritis
with foveolar hyperplasia was identified.
This patient had four additional tumors in the small
intestine, which were found upon examination via video
capsule. The patient underwent endoscopic argon plasma
therapy, which proved to be effective in resolution of urti-
caria. Quality of life greatly improved, with a mean CU-
Q2oL score of 0 after treatment. Urticaria was successfully
treated, with the UAS 7 score dropping to 0.
While endoscopic ablation has been associated with a
high rate of recurrence, it is considered a safe procedure
with 100 % survival, and has been demonstrated to be
effective. We recommend further endoscopic follow-up
to screen any possible recurrence.
Guidelines on follow up management of patients who
have had endoscopic ablation of type I gastric carcinoid
tumors have not yet been established. However, Yarzu et
al. reported using omalizumab in postoperative care of a
male patient with food allergy with pulmonary carcin-
oid tumor. In the post-surgery period the patient had
recurrent laryngeal edema and urticaria attacks. Omalizu-
mab treatment was prescribed because the patient was re-
sistant to anti-histamines and steroids and was used
for eight months in symptomatic therapy of recurrent
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laryngeal edema and urticaria attacks During the four
years of follow up, no carcinoid tumor recurrence was
noted [17].
Conclusions
There are only a few reported cases of urticaria or angio-
edema associated with carcinoid tumors [4, 18]. The case
reported here is particularly interesting because the tu-
mors were located in the foregut. Foregut tumors gener-
ally do not secrete as much of the urticaria mediator kinin
as do midgut tumors, and only secrete a small amount of
the possible mediator serotonin [19]. However, foregut
tumors may secrete 5-hydroxytryptophan (5-HTP), hista-
mine or adrenocorticotropic hormone [2, 20]. Histamine
release could lead to urticaria, which should respond to
H1-antagonists [20]. Our patient was treated with H1
antagonists without response.
This patient presented with urticaria and angioedema
as symptoms. Remarkably, urticaria was the reason for
medical consultation. The patient had no diarrhea, and no
signs or symptoms of bronchoconstriction or heart failure.
This, then, would not fit the definition of a classical car-
cinoid syndrome [21]. The patient also presented with
hypergastrinemia and anemia. This anemia can be attrib-
uted to several etiologies, since RDW was high, and aniso-
cytosis, microcytosis and megaloblasts were observed. The
patient presented chronic autoimmune gastritis, with high
titers of anti-parietal cell antibodies, suggesting parietal
cell loss as the etiology of G cell hyperplasia.
We strongly encourage all physicians who are looking
for the etiology of any chronic urticaria, be they allergists,
dermatologists, internists or primary care physicians, to
consider the possibility of neuroendocrine malignancies
and to screen these patients for elevated anti-parietal cell
antibodies.
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